Peter Verhamme to Respiration, Artificial
This is a "connection" page, showing publications Peter Verhamme has written about Respiration, Artificial.
Connection Strength
0.009
-
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
Score: 0.009